Stay updated on Satralizumab in Thyroid Eye Disease Clinical Trial
Sign up to get notified when there's something new on the Satralizumab in Thyroid Eye Disease Clinical Trial page.

Latest updates to the Satralizumab in Thyroid Eye Disease Clinical Trial page
- Check7 days agoChange DetectedUpdated the study locations: new sites across multiple regions have been added and some sites removed, resulting in revised location availability and contact details on the Study Details page.SummaryDifference1%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe revision label updated from v3.3.1 to v3.3.2; no visible changes to study content.SummaryDifference0.0%

- Check35 days agoChange DetectedPublications section wording updated to indicate PubMed publications are automatically filled from PubMed and may not be about the study; the revision tag was updated from v3.2.0 to v3.3.1.SummaryDifference0.1%

- Check43 days agoChange DetectedA new publication reference about Satralizumab in Thyroid Eye Disease was added to Publications, and a government funding lapse notice along with an older PubMed citation were removed.SummaryDifference0.3%

- Check50 days agoChange DetectedAdded study site names Centro Oftalmologico Dr. Charles S.A., Medizinische Universitat Wien, and Universitatsklinikum Munster. Removed the previous diacritic-heavy spellings Centro Oftalmológico Dr. Charles S.A., Medizinische Universität Wien, Universitätsklinikum Münster from the Locations section.SummaryDifference0.3%

- Check78 days agoChange DetectedAdded new Publications section with a PubMed-listed 2025 study design for satralizumab in thyroid eye disease; no deletions present. This expands the core content with up-to-date research references.SummaryDifference3%

Stay in the know with updates to Satralizumab in Thyroid Eye Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Satralizumab in Thyroid Eye Disease Clinical Trial page.